Hepatitis is inflammation of the liver characterized by yellowed eyes and skin due to bilirubin, flu-like symptoms which include nausea, vomiting, poor appetite, joint pain, headaches, clay colored stools etc.
This report contains market size and forecasts of Hepatitis C Drugs in Global, including the following market information:
- Global Hepatitis C Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
- Global top five companies in 2021 (%)
The global Hepatitis C Drugs market was valued at 6415.7 million in 2021 and is projected to reach US$ 7975.7 million by 2028, at a CAGR of 3.2% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Anti-Viral Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Hepatitis C Drugs include Gilead sciences, Abbvi, Johnson & Johnson, Merck, Glaxosmithkline, Novartis, Bristol-Myers Squibb and Roche, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Hepatitis C Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hepatitis C Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Hepatitis C Drugs Market Segment Percentages, by Type, 2021 (%)
- Anti-Viral
- Immuno-modulators
- Others
Global Hepatitis C Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Hepatitis C Drugs Market Segment Percentages, by Application, 2021 (%)
Global Hepatitis C Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Hepatitis C Drugs Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Hepatitis C Drugs revenues in global market, 2017-2022 (estimated), ($ millions)
- Key companies Hepatitis C Drugs revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Gilead sciences
- Abbvi
- Johnson & Johnson
- Merck
- Glaxosmithkline
- Novartis
- Bristol-Myers Squibb
- Roche
